Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
38%(3 trials)
Terminated
2(20%)

Phase Distribution

Ph not_applicable
1
10%
Ph phase_2
4
40%
Ph phase_1
4
40%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 24 (40.0%)
Phase 31 (10.0%)
N/A1 (10.0%)

Trials by Status

terminated220%
completed880%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Satraplatin and Prednisone to Treat Prostate Cancer

NCT00634647
completedphase_1

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

NCT01259479
completednot_applicable

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

NCT00499694
completedphase_2

Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca

NCT01289067
completedphase_1

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

NCT00473720
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00634647Phase 2

Satraplatin and Prednisone to Treat Prostate Cancer

Completed
NCT01259479Phase 1

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

Completed
NCT00499694Not Applicable

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Completed
NCT01289067Phase 2

Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca

Completed
NCT00473720Phase 1

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Completed
NCT00093132Phase 1

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

Terminated
NCT00069745Phase 3

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Completed
NCT00370383Phase 2

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Completed
NCT00313456Phase 1

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Terminated
NCT00265655Phase 2

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10